Skip to content

Study · Animal study (in vivo) · mouse · 2026

13 results

NMN protects cisplatin-associated AKI via NAD+/SIRT1 pathway.

Wen Z, Wang J, Yang Y, Chen L, Ji X, Liu D, Shi C

Frontiers in immunology4 Feb 2026Cited by 1 (Europe PMC)

PMID41716411 (opens in a new tab)PMCIDPMC12913174 (opens in a new tab)DOI10.3389/fimmu.2026.1721884 (opens in a new tab)PepBankPUB-41716411
Download PDFPubMedAsk about this study
Jump to 13 results

Summary

Acute kidney injury (AKI) is a critical public health concern with high morbidity and mortality. The chemotherapy agent cisplatin is widely used for various solid tumors; however, cisplatin-associated AKI (CIS-AKI) is a frequent complication in the clinic. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to metabolism and redox reactions. β-Nicotinamide mononucleotide (NMN), a key precursor of NAD+, has shown protective effects in various disease models, but its role in CIS-AKI remains unclear. In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN. Bulk RNA sequencing revealed marked inflammatory activation and disruption of NAD+ metabolism in cisplatin-treated mouse kidneys. NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1. It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation. Consistently, in vitro, NMN attenuated cisplatin-induced reactive oxygen species (ROS) generation and lactate dehydrogenase (LDH) release in HK-2 cells. Mechanistically, NMN elevated kidney NAD+ levels and enhanced SIRT1 expression. These findings demonstrate that NMN protects against CIS-AKI by activating the NAD+-SIRT1 pathway, thereby reducing oxidative stress and inflammation, and suggest its potential as a therapeutic strategy for CIS-AKI.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN reduced plasma creatinine.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced blood creatinine.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreasePlasma creatinine
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN reduced blood urea nitrogen.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced blood urea nitrogen.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseBlood urea nitrogen
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN attenuated tubular injury.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced damage to kidney tubules.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseTubular injury
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN decreased NGAL expression.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced the injury marker NGAL.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseNGAL expression
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN decreased KIM-1 expression.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced the injury marker KIM-1.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseKIM-1 expression
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN administration significantly ameliorated kidney dysfunction, as indicated by reduced plasma creatinine and blood urea nitrogen (BUN) levels, attenuated tubular injury, and decreased expression of kidney injury markers NGAL and KIM-1.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN reduced kidney IL-6 levels.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced the inflammatory protein IL-6.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseKidney IL-6 levels
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN reduced kidney IL-18 levels.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced the inflammatory protein IL-18.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseKidney IL-18 levels
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN diminished kidney neutrophil infiltration.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced neutrophil entry into kidneys.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseNeutrophil infiltration
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-associated AKI, NMN diminished kidney macrophage accumulation.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN reduced macrophage accumulation in kidneys.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseMacrophage accumulation
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Immune response · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also markedly suppressed kidney inflammation, characterized by reduced IL-6 and IL-18 levels, diminished neutrophil infiltration and macrophage accumulation.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-associated AKI, NMN elevated kidney NAD levels.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN increased kidney NAD levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseKidney NAD levels
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, NMN elevated kidney NAD+ levels and enhanced SIRT1 expression.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-associated AKI, NMN enhanced kidney SIRT1 expression.

    In plain wordsIn mice with cisplatin-related kidney injury, NMN increased kidney SIRT1 expression.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSIRT1 expression
    Study

    mousen: not reported in source

    male mice with cisplatin-associated acute kidney injury
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, NMN elevated kidney NAD+ levels and enhanced SIRT1 expression.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  12. 12LabIn vitro (cells)Efficacy outcome

    In cisplatin-treated HK-2 cells, NMN attenuated reactive oxygen species generation.

    In plain wordsIn cells exposed to cisplatin, NMN reduced reactive oxygen species production.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseROS generation
    Study

    n: not reported in source

    cisplatin-treated HK-2 cells
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consistently, in vitro, NMN attenuated cisplatin-induced reactive oxygen species (ROS) generation and lactate dehydrogenase (LDH) release in HK-2 cells.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.
  13. 13LabIn vitro (cells)Efficacy outcome

    In cisplatin-treated HK-2 cells, NMN attenuated lactate dehydrogenase release.

    In plain wordsIn cells exposed to cisplatin, NMN reduced release of a cell damage marker.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseLDH release
    Study

    n: not reported in source

    cisplatin-treated HK-2 cells
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consistently, in vitro, NMN attenuated cisplatin-induced reactive oxygen species (ROS) generation and lactate dehydrogenase (LDH) release in HK-2 cells.
    1 context sentence
    Summary · context
    In this study, male mice subjected to CIS-AKI and cisplatin-treated HK-2 cells were employed as in vivo and in vitro models, respectively, to evaluate the renoprotective effects of NMN.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.